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Objective. Aldosterone and high-density lipoprotein cholesterol (HDL-C) are involved in many pathophysiological processes that
contribute to the development of cardiovascular diseases. Previously, associations between the concentrations of aldosterone and
certain components of the lipid metabolism in the peripheral circulation were suggested, but data from the general population is
sparse. We therefore aimed to assess the associations between aldosterone and HDL-C, low-density lipoprotein cholesterol
(LDL-C), total cholesterol, triglycerides, or non-HDL-C in the general adult population. Methods. Data from 793 men and 938
women aged 25–85 years who participated in the ﬁrst follow-up of the Study of Health in Pomerania were obtained. The
associations of aldosterone with serum lipid concentrations were assessed in multivariable linear regression models adjusted for
sex, age, body mass index (BMI), estimated glomerular ﬁltration rate (eGFR), and HbA1c. Results. The linear regression models
showed statistically signiﬁcant positive associations of aldosterone with LDL-C (β-coeﬃcient = 0.022, standard error = 0.010,
p = 0 03) and non-HDL-C (β-coeﬃcient = 0.023, standard error = 0.009, p = 0 01) as well as an inverse association of
aldosterone with HDL-C (β-coeﬃcient =−0.022, standard error = 0.011, p = 0 04). Conclusions. The present data show that
plasma aldosterone is positively associated with LDL-C and non-HDL-C and inversely associated with HDL-C in the
general population. Our data thus suggests that aldosterone concentrations within the physiological range may be related
to alterations of lipid metabolism.
1. Introduction
Cardiovascular diseases are the leading cause of death world-
wide [1]. Among other factors, high low-density lipoprotein
cholesterol (LDL-C) and low high-density lipoprotein cho-
lesterol (HDL-C) concentrations are important risk factors
for cardiovascular disease [2].
Aldosterone, a hormone produced in the zona glomeru-
losa of the adrenal glands, has a major impact on metabolic
pathways and is connected to multiple cardiovascular pathol-
ogies including endothelial dysfunction, thrombosis, and
myocardial as well as vascular ﬁbrosis [3]. Several studies
[4–9] suggest that there may be associations between the con-
centrations of aldosterone and certain components of lipid
metabolism in peripheral circulation. In an experimental
setup including 30 volunteers, Goodfriend et al. [6] described
a negative association between aldosterone and HDL-C and a
positive correlation between aldosterone and triglycerides.
Several other studies [5, 7–9] described associations between
aldosterone and metabolic syndrome, which comprises
elevated serum HDL-C and triglyceride concentrations.
Thus, in 2292 Framingham Oﬀspring Study participants,
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aldosterone was positively associated with incident metabolic
syndrome and inversely with changes in HDL-C [8]. Further-
more, lipid metabolism deteriorated after successful treat-
ment of primary aldosteronism [4].
While these studies [4–9] suggest that there are associ-
ations between aldosterone and the components of lipid
metabolism in certain patient groups, data from the gen-
eral population is sparse. We therefore aimed to assess
the associations between aldosterone and HDL-C, LDL-C,
total cholesterol, triglycerides, or non-HDL-C in the general
adult population.
2. Subjects and Methods
2.1. Study Population. Data were obtained from the ﬁrst
follow-up of the longitudinal Study of Health in Pomerania
(SHIP-1). SHIP is a population-based project in the
northeast of Germany. From the population registration
oﬃces, a representative sample including 7008 adults aged
20 to 79 years was selected. Baseline examinations (SHIP-0)
were conducted between 1997 and 2001 including 4308 sub-
jects. Starting in March 2002, the ﬁrst ﬁve-year follow-up
examination (SHIP-1) was performed. SHIP-1 was ﬁnished
in July 2006 and comprised 3300 participants, who received
aldosterone measurements. Details on study design and
sampling methods are given elsewhere [10]. The study
participants provided information on sociodemographic
characteristics, lifestyle, and medical histories. They further
underwent standardized physical examinations, including
measurements of body height and weight and provided blood
samples. Body mass index (BMI) was calculated as weight
(kg)/height2 (m2). Systolic and diastolic blood pressures were
measured three times on the right arm of seated subjects,
using a digital blood pressure monitor (HEM-705CP, Omron
Corporation, Tokyo, Japan). The mean of the second and
third measurements was used for statistical analyses. Hyper-
tension was deﬁned as systolic blood pressure≥ 140mmHg
or diastolic blood pressure≥ 90mmHg or self-reported
intake of antihypertensive mediation. Diabetes mellitus was
deﬁned when the participants reported a respective physi-
cian’s diagnosis and intake of antidiabetic medication and
had an HbA1c≥ 6.5% or a random glucose concentra-
tion≥ 11.1mmol/l. The participants’ medication was cate-
gorised according to the anatomical-therapeutic-chemical
(ATC) classiﬁcation code. The intake of statins was deﬁned
according to ATC code C10. The intake of antidiabetic
medication was deﬁned according to ATC code A10, oral
contraceptives as ATC code G03A. The intake of medication
that alters aldosterone or renin concentrations was deﬁned as
diuretics including aldosterone antagonists (ATC C03), beta
blockers (ATC C07) or other antiadrenergic agents (ATC
C02), calcium channel blockers (ATC C08), angiotensin con-
verting enzyme inhibitors (ATC C09A-B), or angiotensin
receptor blockers (ATC C09C-D). Of the 3300 participants,
we excluded all those (overlap exists) with missing data on
aldosterone or serum lipid concentrations (n = 36), missing
data on BMI (n = 10) or HbA1c (n = 33), subjects with renal
insuﬃciency (deﬁned as estimated glomerular ﬁltration rate
(eGFR)< 30ml/min/1.73m2), or missing information on
renal function (n = 32); with aldosterone or the aldosterone-
to-renin ratio outside the study-speciﬁc reference range
(n = 287) [11]; and with intake of statins or medication
that alters aldosterone or renin concentrations (RAAS,
n = 1408) and all pregnant women (n = 10). This resulted
in a study population of 1731 subjects.
All participants gave written, informed consent. The
study conformed to the principles of the Declaration of
Helsinki and was approved by the Ethics Committee of the
Board of Physicians Mecklenburg-West Pomerania at the
University of Greifswald.
2.2. Laboratory Measurements. Nonfasting blood samples
were taken from the cubital vein of participants in the supine
position. Aldosterone and renin concentrations were mea-
sured in EDTA plasma by radioimmunometric procedures
(aldosterone: Coat-A-Count Aldosterone, Siemens Health-
care Diagnostics, Eschborn, Germany; renin: Renin III gener-
ation, Cisbio Bioassay, Bagnols-sur-Cèze Cedex, France)
as previously described [11]. The aldosterone-to-renin
ratio was calculated by dividing aldosterone by renin
concentrations. Sodium and potassium concentrations were
determined in serum on the Dimension RxL (Siemens
Healthcare Diagnostics, Eschborn, Germany). Serum lipid
concentrations were quantiﬁed by lipoprotein electrophoresis
(HDL-C and LDL-C: HELENA SAS-3 system; Helena 7
BioSciences Europe, Tyne and Wear, UK) or were measured
on the Dimension RxL (Siemens Healthcare Diagnostics,
Eschborn, Germany). Triglycerides were measured enzymat-
ically and total cholesterol was determined by the CHOD-
PAP method. Non-HDL-C was calculated as diﬀerence
between total and HDL-C.
2.3. Statistical Analyses. General characteristics of the study
population are expressed as medians with 1st–3rd quartiles
(continuous data) or as proportions (categorical data)
according to sex-speciﬁc quartiles of the aldosterone
concentration. Group diﬀerences were tested for statistical
signiﬁcance with chi-squared or Kruskal-Wallis tests. The
associations of aldosterone with serum lipid concentrations
were assessed in multivariable linear regression models
adjusted for sex, age, BMI, eGFR, and HbA1c. We further
assessed the associations of the aldosterone-to-renin ratio
with serum lipid concentrations to examine whether the
associations are driven by aldosterone per se or by the
relation of aldosterone-to-renin. For the regression analy-
ses, we log transformed exposure and outcome variables
to obtain normally distributed residuals. We report β-
coeﬃcients with standard errors and p values. A value
of p < 0 05 was considered statistically signiﬁcant. All
statistical analyses were performed with SAS 9.4 (SAS
Institute Inc., Cary, North Carolina, USA).
3. Results
The study population included 793 men and 938 women
aged 25–86 years (median 47 years, 1st–3rd quartile 37–57
years). Subjects in the highest aldosterone quartile were on
average four years younger than those in the lowest
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aldosterone quartile (42 versus 46 years, p < 0 01, Table 1).
Further group diﬀerences in systolic or diastolic blood pres-
sures, eGFR, HbA1c, or BMI were not statistically signiﬁcant.
Also, total cholesterol, LDL cholesterol, non-HDL choles-
terol, and triglycerides were not signiﬁcantly diﬀerent in
the aldosterone quartiles. In contrast, HDL-C decreased with
increasing aldosterone. Thus, HDL-C was 1.22mmol/l
(1st–3rd quartile 0.95–1.55mmol/l) in the lowest aldosterone
quartile and 1.13mmol/l (1st–3rd quartile 0.90–1.45mmol/l)
in the highest aldosterone quartile (p = 0 04).
The linear regression models (Figure 1) revealed positive
associations of aldosteronewith LDL-C (β-coeﬃcient = 0.022,
standard error = 0.010, p = 0 03) and non-HDL-C (β-coeﬃ-
cient = 0.023, standard error = 0.009, p = 0 01) as well as an
inverse association of aldosterone with HDL-C (β-coeﬃ-
cient =−0.022, standard error = 0.011, p = 0 04), while the
associations with total cholesterol (β-coeﬃcient = 0.010,
standard error = 0.007, p = 0 15) and triglycerides (β-coeﬃ-
cient = 0.029, standard error = 0.020, p = 0 14) were not statis-
tically signiﬁcant. The relations of the aldosterone-to-renin
ratio with the lipid concentrations pointed in the same direc-
tion but none of the examined associations was statistically
signiﬁcant (total cholesterol: β-coeﬃcient = 0.009, standard
error = 0.006, p = 0 17; LDL-C: β-coeﬃcient = 0.012, stan-
dard error = 0.009, p = 0 16; HDL-C: β-coeﬃcient =−0.004,
standard error = 0.010, p = 0 71; non-HDL-C: β-coeﬃ-
cient = 0.015, standard error = 0.009, p = 0 08; and triglycer-
ides: β-coeﬃcient = 0.019, standard error = 0.018, p = 0 30).
4. Discussion
The results of several cross-sectional [5, 7] and longitudinal
[8, 9] studies that included patients with metabolic syndrome
suggest that increased plasma aldosterone is associated
with an altered lipid metabolism, including decreased
HDL-C [5, 7–9] and increased triglycerides [7, 9]. Another
study in 2891 Framingham Oﬀspring Study participants
[12] and without focus on the metabolic syndrome demon-
strated an association between higher aldosterone and an
elevated total/HDL-C ratio but not with HDL-C alone.
Further lipid metabolism components were not evaluated
in this study [12]. Our results conﬁrm the previously
reported inverse association of aldosterone with HDL-C
[5, 7–9], while positive associations of aldosterone with
triglycerides [7, 9] could not be replicated. As major
new ﬁndings, our data show that plasma aldosterone is
positively associated with LDL-C and non-HDL-C in the
general population. As the associations of the aldosterone-
to-renin ratio with lipid concentrations were not statistically
signiﬁcant, increasing aldosterone per se seems to control
the observed associations.
Our data and the results of the abovementioned studies
[5, 7–9, 12] suggest that high aldosterone may have a negative
eﬀect on circulating lipid concentrations. This in turn may
contribute to the cardiovascular damage observed with
inappropriately high aldosterone concentrations [13]. The
detrimental eﬀect of aldosterone is most impressively
Table 1: Characteristics of the study population.
Characteristics
Quartiles of the plasma aldosterone concentration (PAC)
p
Q1 (n = 415) Q2 (n = 435) Q3 (n = 447) Q4 (n = 434)
Male (%) 45.1 46.4 45.9 45.9 0.98
Age (years) 46.0 (37.0–58.0) 46.0 (37.0–58.0) 45.0 (37.0–57.0) 42.0 (35.0–53.0) <0.01
BMI (kg/m2) 25.7 (23.6–29.1) 25.7 (23.2–28.2) 26.4 (23.6–29.1) 26.2 (23.1–29.8) 0.21
HbA1c (%) 5.20 (4.90–5.50) 5.10 (4.80–5.50) 5.10 (4.80–5.50) 5.10 (4.70–5.40) 0.11
Diabetes mellitus (%) 5.30 4.61 3.80 6.00 0.48
eGFR (ml/min/1.73m2) 89.8 (78.8–103.8) 89.0 (78.6–102.5) 89.1 (76.0–100.8) 89.2 (78.3–99.8) 0.50
Systolic blood pressure (mmHg) 125 (115–137) 127 (114–138) 126 (116–139) 124 (115–137) 0.47
Diastolic blood pressure (mmHg) 79.5 (74.0–86.0) 79.5 (73.5–87.0) 80.5 (75.0–88.0) 80.5 (74.0–88.5) 0.34
Hypertension (%) 25.3 26.0 28.6 27.3 0.70
Intake of oral contraceptives (%)∗ 13.6 15.9 8.26 14.5 0.07
PAC (ng/l) 17.0 (12.0–21.0) 33.0 (28.0–38.0) 49.0 (43.0–54.0) 78.0 (67.0–96.0) <0.01
PRC (ng/l) 6.50 (4.50–9.00) 7.60 (4.70–10.70) 8.30 (5.40–11.70) 10.05 (7.30–14.90) <0.01
ARR 2.43 (1.59–3.57) 4.51 (2.99–6.59) 6.17 (4.10–8.62) 7.90 (5.66–11.04) <0.01
Potassium (mmol/l) 4.26 (4.08–4.50) 4.30 (4.10–4.50) 4.32 (4.18–4.59) 4.37 (4.13–4.58) <0.01
Sodium (mmol/l) 139 (138–141) 139 (138–141) 139 (138–141) 139 (138–141) 0.18
Total cholesterol (mmol/l) 5.37 (4.70–6.20) 5.60 (0.97–6.40) 5.51 (4.80–6.24) 5.40 (4.70–6.30) 0.26
LDL cholesterol (mmol/l) 3.35 (2.81–4.04) 3.56 (2.80–4.36) 3.54 (2.86–4.17) 3.42 (2.85–4.20) 0.28
HDL cholesterol (mmol/l) 1.22 (0.95–1.55) 1.20 (0.97–1.50) 1.16 (0.89–1.49) 1.13 (0.90–1.45) 0.04
Non-HDL cholesterol (mmol/l) 4.10 (3.43–4.94) 4.31 (3.42–5.25) 4.33 (3.45–5.10) 4.24 (3.45–5.09) 0.34
Triglycerides (mmol/l) 1.20 (0.83–1.92) 1.30 (0.88–2.03) 1.28 (0.88–1.98) 1.36 (0.88–1.95) 0.29
Data are median (1st–3rd quartile) or proportions. Group diﬀerences were tested with chi-squared or Kruskal-Wallis tests. ∗Intake of oral contraceptives in
women. ARR: aldosterone-to-renin ratio; BMI: body mass index; eGFR: estimated glomerular ﬁltration rate; HDL-C: high-density lipoprotein cholesterol;
LDL-C: low-density lipoprotein cholesterol; PRC: plasma renin concentration.
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observed in patients with primary aldosteronism, a serious
condition with extremely high aldosterone concentrations.
Primary aldosteronism causes hypertension, and patients
commonly have a high cardiovascular risk [14] and wide
range of comorbidities [15]. Yet, a recent study [4] reported
that successful treatment of primary aldosteronism resulted
in increased serum LDL-C and triglyceride levels as well as
decreased HDL-C levels. While these results seem counterin-
tuitive at ﬁrst sight, the worsening lipid proﬁle under surgical
or medical therapy might not result in a higher cardiovascu-
lar risk. Instead, the manifold therapy beneﬁts, including a
lowering of blood pressure, probably outweigh the adverse
lipid changes [15]. In addition, the eﬀects observed in pri-
mary aldosteronism may not be representative of the general
population. Apart from primary aldosteronism, negative
eﬀects of increasing aldosterone have been reported in
several studies, for example, in patients with chronic heart
failure [16], myocardial infarction [17], or the general popu-
lation [18]. In these studies [16–18], increasing aldosterone
was related to an elevated cardiovascular mortality [17, 18]
or incident hypertension [16]. Whether our ﬁndings of
increasing LDL-C and non-HDL-C and decreasing HDL-C
with increasing aldosterone contribute to incident cardiovas-
cular events in the general population and whether a lower-
ing of circulating aldosterone concentrations may be
cardioprotective cannot be answered by our cross-sectional
study. However, previous studies point into that direction
[19, 20]. Thus, a combined RAAS blockade with an
angiotensin-converting enzyme inhibitor and an angiotensin
II AT1 receptor blocker led to increased HDL-C and
decreased LDL-C levels in patients with diabetes and hyper-
tension [20]. Moreover, treatment with mineralocorticoid
receptor antagonists in addition to standard therapy
improved cardiovascular morbidity and mortality in heart
failure patients [19].
The mechanisms underlying the associations between
circulating aldosterone and lipid concentrations are currently
poorly understood, but a brought range of pathophysiologi-
cal explanations has been discussed. The most evident
approach relates to the link between obesity and RAAS activ-
ity. Adipose tissue, via secretion of factors such as leptin,
stimulates adrenal aldosterone secretion [21]. Aldosterone,
via the mineralocorticoid receptor, may in turn mediate
adipocyte diﬀerentiation, thereby contributing to adipo-
genesis and inﬂammation [22–24]. Indeed, BMI and
aldosterone were closely linked in our study. A linear
regression model adjusted for age and sex demonstrated a
positive relation between the measures (β-coeﬃcient = 0.010,
standard error = 0.004, p < 0 01). Nevertheless, the associa-
tions between aldosterone and LDL-C, HDL-C, and
non-HDL-C remained signiﬁcant after adjustment for
BMI. Another approach linking aldosterone and lipid
concentrations aims at HDL-C, which may directly inhibit
adrenal aldosterone secretion by modulating the sensitivity
of the adrenal zona glomerulosa [6]. Other studies
(reviewed by Trevisan et al. [25]) showed that high
aldosterone concentrations may induce kidney injury and
proteinuria. The herewith associated loss of albumin, lipo-
proteins, and liver proteins may aﬀect LDL-C and HDL-C
synthesis [26].
The present study stands out due to its large sample size
as well as comprehensive and standardized data collection.
Limitations arise from the observational study design, which
implies that the results of this study cannot be interpreted in
a causal way. Our cross-sectional analysis is further not
suited to draw conclusions on related incident cardiovascular
outcomes. Moreover, data on salt or water intake of the study
participants was not collected. While we have no reason to
assume that our study participants consume more than
average amounts of salt or water, we also cannot exclude
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Figure 1: Associations between plasma aldosterone concentration
(PAC) and serum lipid concentrations. Results from multivariable
linear regression analyses adjusted for age, sex, body mass index,
estimated glomerular ﬁltration rate, and HbA1c. β-coeﬃcients,
standard errors (stderr), and p values are given. PAC and the
serum lipid concentrations were log transformed before being
entered in the regression models and back transformed for the
illustration in the ﬁgure. The y-axis is log scaled.
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that single individuals may do so. Finally, insights into
the pathophysiology of the topic cannot be generated by
our study.
Taken together, the present data show that plasma
aldosterone is positively associated with LDL-C and non-
HDL-C in the general population. Furthermore, our study
conﬁrms the previously reported inverse association of
plasma aldosterone with HDL-C. Our data suggest that
aldosterone concentrations within the physiological range
may be related to alterations of lipid metabolism.
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